Halozyme wins court order to block Merck's injected Keytruda in select European markets
Halozyme won a Dutch court order blocking Merck from selling injectable Keytruda in eight European markets, citing patent infringement of its MDASE technology. Merck's subcutaneous Keytruda SC was expected to drive growth. Halozyme has also sued Merck in the US and Germany. Merck did not comment.
How this was made
The 30-second read
Why it matters
The decision blocks a major growth driver for Merck while strengthening Halozyme's patent portfolio.
Market read
The injunction creates immediate downside risk for Merck and upside potential for Halozyme, with broader implications for biotech patent risk.
What to watch
Potential for Merck to negotiate a licensing deal with Halozyme, which could offset losses.
Background
A Dutch patent court found Merck infringed Halozyme's MDASE technology, ordering a halt to Keytruda SC in eight European countries.
Ticker impact
Dutch court ordered Merck to halt production and sale of injectable Keytruda in eight European markets.
likely pressure as the market prices in the injunction and loss of Keytruda SC revenue.
The injunction stops a key growth product in multiple countries, reducing near‑term revenue.
Halozyme won a patent infringement case against Merck, securing a court order blocking Keytruda SC in Europe.
likely upside as the market values the strengthened patent position and possible settlements.
The ruling validates Halozyme's technology and may lead to licensing fees or settlements.
Market effects
Biopharma sector may see heightened focus on patent litigation risk.
European markets for oncology drugs could experience short‑term volatility.
Keytruda is a global oncology product; the injunction may affect worldwide sales forecasts.
Counterpoint
Merck could mitigate impact by accelerating other formulations or pursuing appeals.
Key entities
- CompanyHalozyme Therapeutics
Biopharma company holding patents on MDASE drug delivery technology.
- CompanyMerck & Co.
Pharmaceutical giant developing Keytruda SC.
